Rosetta Genomics (NASDAQ:ROSG-OLD) jumps 10.6% premarket after saying the peer-reviewed journal Molecular Cancer, has accepted a manuscript outlining the ability of the company's miRview test (I, II) to accurately "identify the tumor of origin." In short, the test's predictions agreed with the final diagnosis in 92% of the 84 patients from which samples were taken. (PR)